RJ . Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study . Gynecol Oncol 1991 ; 40 : 55 – 65 . 5 FIGO . Corpus cancer staging
Search Results
Meaghan Tenney and Joan L. Walker
Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
The NCCN Guidelines 1) describe risk factors for lung cancer; 2) recommend criteria for selecting individuals with high-risk factors for screening; 3) provide recommendations for evaluation and follow-up of lung nodules found during screening; 4
Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Courtney Smith
DNMT3A, U2AF1, SRSF2, CBL, PRPF8, SETBP1 , and KRAS . 23 , 26 , 29 – 32 Mutations of SF3B1 have been associated with a more favorable prognosis, but this may not be an independent risk factor. 26 , 33 Mutations of TP53 are strongly associated
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
cancer, requiring specific multimodality approaches. This article reviews the biology, risk factors, and evolving treatment of LARC. Important advances have been made in the past 3 decades in the multimodality treatment of patients with LARC. In the
Shaneli A. Fernando and Stephen B. Edge
with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials . J Clin Oncol 2004 ; 22 : 4247 – 4254 . 7. Wallgren A Bonetti M Gelber RD . Risk factors
Myron Goldsmith, George Whitelaw, and Denise A. Cannaday
. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients . Cancer 2007 ; 110 : 2339 – 2346 . 11. Wagman LD Baird MF Bennett CL . NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic
Breast cancer risk factor analysis allows the identification of women at very high risk for the future development of breast cancer. However, estimating risk for the individual woman is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. These practice guidelines discuss known risk factors, strategies for reducing risk, and possible future developments.
For the most recent version of the guidelines, please visit NCCN.org
Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole
/print certificate. Release date: May 13, 2013; Expiration date: May 13, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Identify the risk factors associated with penile cancer. Discuss the rationale for
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich
patients with non–small cell lung cancer treated using atezolizumab monotherapy, we analyzed the incidence, severity, time course, treatment, outcomes, and risk factors of various organ-specific irAEs and their relationships with response rates
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
treatment remains high. We performed a retrospective cohort analysis using population-based data to evaluate new and persistent opioid and benzodiazepine use and risk factors among patients with breast cancer who received curative-intent treatment. Methods
